Cargando…
Oncolytic Virotherapy for High-Grade Glioma and Current Evidence and Factors to Consider for Incorporation into Clinical Practice
Brain tumor incidence is on the rise, and glioblastoma comprises the majority of primary tumors. Despite maximal safe resection and adjuvant chemoradiation, median survival for high-grade glioma remains poor. For this reason, it is important to develop and incorporate new treatment strategies. Oncol...
Autores principales: | Soldozy, Sauson, Eichberg, Daniel G., Morell, Alexis A., Luther, Evan, Lu, Victor M., Higgins, Dominique M. O., Patel, Nitesh V., Shah, Ashish H., Hanft, Simon J., Komotar, Ricardo J., Ivan, Michael E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386040/ https://www.ncbi.nlm.nih.gov/pubmed/37513708 http://dx.doi.org/10.3390/pathogens12070861 |
Ejemplares similares
-
Oncolytic Virotherapy for Melanoma Brain Metastases, a Potential New Treatment Paradigm?
por: Soldozy, Sauson, et al.
Publicado: (2021) -
Oncolytic Virotherapy in Glioma Tumors
por: Rius-Rocabert, Sergio, et al.
Publicado: (2020) -
Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?
por: Koks, Carolien A.E., et al.
Publicado: (2015) -
COVD-18. POTENTIAL TO HARNESS SARS-COV-2 NEUROTROPISM IN THE DELIVERY OF ONCOLYTIC VIROTHERAPY FOR THE TREATMENT OF HIGH-GRADE GLIOMA
por: Immidisetti, Amanda, et al.
Publicado: (2020) -
ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012)